Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Aqneursa Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0715

    Aqneursa

    Customize your policy alerts

    Sign up for Cigna Policy IP0715 alerts

    Get alerted when Policy IP0715 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Cigna drug coverage policy governs prior authorization and benefit coverage for Aqneursa (levacetylleucine oral suspension). It applies to health benefit plans administered by Cigna Companies, subject to the member's specific benefit plan, applicable law, and the clinical criteria in the policy.

    Policy Summary
    PayerCigna
    PolicyAqneursa
    Policy CodePolicy IP0715
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewOct 16, 2025
    Next Review DateNot specified
    Key ActionObtain prior authorization and have Aqneursa prescribed by or in consultation with a specialist in the condition being treated.
    SourceLink
    POLICY UPDATE CHANGES

    The initial approval duration for Niemann-Pick disease type C was changed from 6 months to 1 year.

    Ataxia-Telangiectasia was added as a new FDA-approved indication with new initial- and continuation-therapy criteria.

    Ataxia-Telangiectasia was removed from the Conditions Not Covered section.

    PA requiredCoverage requirement
    2Covered indications
    1 yearInitial approval duration
    ≥4 years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum patient age
    ≥15 kgMinimum patient weight
    MiplyffaCombination use excluded

    Covered and Non-Covered Uses

    Niemann-Pick disease type C

    Covered when ONE of the following pathways is met:

    Niemann-Pick disease type C coverage pathways

    • Initial therapy: The patient is at least 4 years of age; weighs at least 15 kg; has one or more neurologic symptoms of Niemann-Pick disease type C; diagnosis is established by genetic testing showing biallelic pathogenic variants in either the NPC1 gene or NPC2 gene; and Aqneursa is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, neurologist, or physician who specializes in the treatment of Niemann-Pick disease type C or related disorders.Age ≥4 years; weight ≥15 kg; approval for 1 year

      Documentation is required for neurologic symptoms and genetic testing.

    • Currently receiving Aqneursa: According to the prescriber, the patient has derived benefit from treatment, defined as disease stabilization, slowed progression, or improvement; and Aqneursa is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, neurologist, or physician who specializes in the treatment of Niemann-Pick disease type C or related disorders.Approval for 1 year

      Continuation requires prescriber-documented benefit.

    Ataxia-Telangiectasia

    Covered when ONE of the following pathways is met:

    Ataxia-Telangiectasia coverage pathways

    • Initial therapy: The patient is at least 4 years of age; weighs at least 15 kg; has one or more ataxia signs or symptoms of Ataxia-Telangiectasia; diagnosis is established by genetic testing showing biallelic pathogenic or likely pathogenic variants in ATM; and Aqneursa is prescribed by or in consultation with a geneticist, neurologist, or physician who specializes in the treatment of Ataxia-Telangiectasia or related disorders.Age ≥4 years; weight ≥15 kg; approval for 1 year

      Documentation is required for ataxia signs or symptoms and genetic testing.

    • Currently receiving Aqneursa: According to the prescriber, the patient has derived benefit from treatment, defined as disease stabilization, slowed progression, or improvement; and Aqneursa is prescribed by or in consultation with a geneticist, neurologist, or physician who specializes in the treatment of Ataxia-Telangiectasia or related disorders.Approval for 1 year

      Continuation requires prescriber-documented benefit.

    Combination use of Aqneursa with Miplyffa (arimoclomol capsules) is considered not medically necessary because no data are available regarding use of the two medications together.

    Use of Aqneursa for GM2 gangliosidoses, including Tay-Sachs disease and Sandhoff disease, is considered not medically necessary. Additional study is needed to establish the treatment’s role for these conditions.

    Aqneursa is considered not medically necessary for any use outside the covered FDA-approved indications addressed in this policy.

    Aqneursa is considered not medically necessary when used in combination with Miplyffa, for GM2 gangliosidoses including Tay-Sachs and Sandhoff diseases, or for any other use outside the covered FDA-approved indications.

    Key Patient Thresholds

    Age threshold
    Minimum ageAt least 4 years
    Applies toInitial therapy for Niemann-Pick disease type C and Ataxia-Telangiectasia
    Coverage requirementThe patient must meet the minimum age requirement for initial-therapy approval
    Weight threshold
    Minimum weightAt least 15 kg
    Applies toInitial therapy for Niemann-Pick disease type C and Ataxia-Telangiectasia
    Coverage requirementThe patient must meet the minimum weight requirement for initial-therapy approval

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Aqneursa. Approvals are issued for the duration specified in the coverage criteria; when approval is stated in months, 1 month equals 30 days.

    Prior Authorization

    Specialist Prescribing or Consultation Required

    Aqneursa must be prescribed by, or prescribed in consultation with, a physician who specializes in the condition being treated. Specialist involvement is required because of the specialized skills needed to evaluate and diagnose these patients and to monitor adverse events and long-term efficacy.

    • For Niemann-Pick disease type C: geneticist, endocrinologist, metabolic disorder subspecialist, neurologist, or physician specializing in Niemann-Pick disease type C or related disorders.
    • For Ataxia-Telangiectasia: geneticist, neurologist, or physician specializing in Ataxia-Telangiectasia or related disorders.

    Clinical Background

    Niemann-Pick disease type C (NPC) is an autosomal recessive, progressive lysosomal storage disorder caused by mutations primarily in NPC1 or NPC2. These mutations impair cholesterol binding and transport, leading to lipid accumulation in the brain, liver, and spleen and producing variable visceral, neurologic, and psychiatric manifestations.

    Policy Definitions

    Niemann-Pick disease type C
    InheritanceAutosomal recessive disorder
    Disease typeProgressive lysosomal storage disorder
    Genetic causesMutations in NPC1 or NPC2
    Disease mechanismDeficient cholesterol binding and transport causes lipid accumulation in the brain, liver, and spleen
    Ataxia-telangiectasia
    InheritanceAutosomal recessive disorder
    Neurologic featureProgressive cerebellar degeneration

    Initial Therapy

    Initial therapy

    Approve for 1 year when all applicable indication-specific requirements are met.

    Applicable indication

    • Niemann-Pick disease type C: The patient is at least 4 years of age; weighs at least 15 kg; has one or more neurologic symptoms of Niemann-Pick disease type C; diagnosis is established by genetic testing showing biallelic pathogenic variants in either the NPC1 gene or NPC2 gene; and Aqneursa is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, neurologist, or physician who specializes in the treatment of Niemann-Pick disease type C or related disorders.Age ≥4 years; weight ≥15 kg

      Documentation is required for neurologic symptoms and genetic testing.

    • Ataxia-Telangiectasia: The patient is at least 4 years of age; weighs at least 15 kg; has one or more ataxia signs or symptoms of Ataxia-Telangiectasia; diagnosis is established by genetic testing showing biallelic pathogenic or likely pathogenic variants in ATM; and Aqneursa is prescribed by or in consultation with a geneticist, neurologist, or physician who specializes in the treatment of Ataxia-Telangiectasia or related disorders.

    Continuation Therapy

    Continuation therapy

    Approve for 1 year when the patient is currently receiving Aqneursa and meets BOTH requirements.

    Continuation therapy: The patient is currently receiving Aqneursa; the prescriber reports treatment benefit, defined as disease stabilization, slowed progression, or improvement; and Aqneursa is prescribed by or in consultation with the specialist required for the applicable indication.Approval for 1 year

    The required specialist is indication-specific: for Niemann-Pick disease type C, a geneticist, endocrinologist, metabolic disorder subspecialist, neurologist, or physician specializing in Niemann-Pick disease type C or related disorders; for Ataxia-Telangiectasia, a geneticist, neurologist, or physician specializing in Ataxia-Telangiectasia or related disorders.

    Policy Summary
    PayerCigna
    PolicyAqneursa
    Policy CodePolicy IP0715
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewOct 16, 2025
    Next Review DateNot specified
    Key ActionObtain prior authorization and have Aqneursa prescribed by or in consultation with a specialist in the condition being treated.
    SourceLink
    On This Page
    Covered and Non-Covered UsesKey Patient ThresholdsAuthorization, Documentation, and Denial RisksClinical BackgroundPolicy DefinitionsInitial TherapyContinuation Therapy
    Documentation Required

    Required Supporting Documentation

    Submit patient-specific supporting documentation demonstrating that the applicable coverage criteria are met. Documentation must include patient-specific identifying information.

    • Chart notes and medical records.
    • Laboratory tests and other medical test results.
    • Claims records, prescription receipts, and/or other relevant information.
    • For required diagnoses: genetic test results establishing the specified biallelic pathogenic or likely pathogenic variants.
    Documentation Required

    Document Criteria-Specific Evidence

    Provide documentation wherever the criteria identify [documentation required]. Supporting evidence may include chart notes, laboratory tests, medical test results, claims records, prescription receipts, and other information needed to substantiate the patient’s clinical findings, diagnosis, or treatment response.

    • Document neurologic symptoms of Niemann-Pick disease type C or ataxia signs or symptoms of Ataxia-Telangiectasia, as applicable.
    • For continuation therapy, document prescriber-reported benefit, defined as disease stabilization, slowed progression, or improvement.
    Denial Risk

    Non-Covered Uses

    Aqneursa is not medically necessary for uses outside the covered FDA-approved indications. This includes combination use with Miplyffa (arimoclomol capsules); no data are available regarding combination use of Miplyffa and Aqneursa.

    • Do not submit Aqneursa in combination with Miplyffa.
    • Other uses, including GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases), are not covered under this policy.
    Denial Risk

    Failure to Meet Criteria May Result in Denial

    Coverage may be denied when the patient does not meet all applicable clinical criteria for the requested indication and therapy phase. For initial therapy, verify age, weight, disease-specific findings, genetic confirmation, and specialist involvement; for continuation therapy, verify documented benefit and specialist involvement.

    • Niemann-Pick disease type C initial therapy: patient must be at least 4 years old, weigh at least 15 kg, have one or more neurologic symptoms, have biallelic pathogenic variants in NPC1 or NPC2, and meet the specialist prescribing or consultation requirement.
    • Ataxia-Telangiectasia initial therapy: patient must be at least 4 years old, weigh at least 15 kg, have one or more ataxia signs or symptoms, have biallelic pathogenic or likely pathogenic variants in ATM, and meet the specialist prescribing or consultation requirement.
    • Continuation therapy for either indication: the prescriber must document disease stabilization, slowed progression, or improvement, and the specialist prescribing or consultation requirement must continue to be met.
    Other characteristic featuresTelangiectasia and immunodeficiency
    Associated complicationsRecurrent sinopulmonary infections, radiation sensitivity, premature aging, and increased cancer risk
    Aqneursa
    MedicationLevacetylleucine
    FormulationOral suspension
    Brand nameAqneursa
    Manufacturer/marketerIntraBio
    Neurologic symptoms of Niemann-Pick disease type C
    Motor functionLoss of motor function
    SwallowingDifficulty swallowing
    Communication and cognitionSpeech or cognitive impairment
    Ataxia signs and symptoms
    GaitGait ataxia
    Truncal controlTruncal ataxia
    Eye movementsOculomotor ataxia
    BalanceDifficulties with balance
    Speech and coordinationDifficulties with speech and hand coordination
    Derived benefit from treatment
    Disease stabilizationStabilization of the disease
    Slowed progressionSlowed disease progression
    ImprovementImprovement in the patient’s condition
    Documentation sourceBenefit is reported by the prescriber
    Age ≥4 years; weight ≥15 kg

    Documentation is required for ataxia signs or symptoms and genetic testing.